Cargando…
Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis
Despite widespread use of statins to reduce low-density lipoprotein cholesterol (LDL-C) and associated atherosclerotic cardiovascular risk, many patients do not achieve sufficient LDL-C lowering due to muscle-related side effects, indicating novel treatment strategies are required. Bempedoic acid (E...
Autores principales: | Pinkosky, Stephen L., Newton, Roger S., Day, Emily A., Ford, Rebecca J., Lhotak, Sarka, Austin, Richard C., Birch, Carolyn M., Smith, Brennan K., Filippov, Sergey, Groot, Pieter H.E., Steinberg, Gregory R., Lalwani, Narendra D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133702/ https://www.ncbi.nlm.nih.gov/pubmed/27892461 http://dx.doi.org/10.1038/ncomms13457 |
Ejemplares similares
-
Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase
por: Bilen, Ozlem, et al.
Publicado: (2016) -
LDL-cholesterol reduction in patients with hypercholesterolemia by modulation of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase
por: Filippov, Sergey, et al.
Publicado: (2014) -
Allosteric role of the citrate synthase homology domain of ATP citrate lyase
por: Wei, Xuepeng, et al.
Publicado: (2023) -
Exploring the Role of ATP-Citrate Lyase in the Immune System
por: Dominguez, Monica, et al.
Publicado: (2021) -
Macrophage ATP citrate lyase deficiency stabilizes atherosclerotic plaques
por: Baardman, Jeroen, et al.
Publicado: (2020)